Humacyte prices $20M registered direct offering

Humacyte (HUMA) has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common stock pursuant to a registered direct offering. The offering was led by a new life science dedicated investor and a long-only mutual fund. The gross proceeds from this offering are expected to be $20 million, before deducting offering expenses. The offering is expected to close on or about March 20, 2026, subject to satisfaction of customary closing conditions. All of the shares of common stock are being sold by Humacyte. Titan Partners, a division of American Capital Partners, is acting as sole placement agent for the offering.